Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew L Frelinger

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
Immunity|January 7, 2022
Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemiaValentina Poli, Marco Di Gioia, Martha Sola-Visner, et al.
The American Journal of Cardiology|October 30, 2003
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregationAndrew L Frelinger, Mark I Furman, Marc R Barnard, et al.
Journal of the American Heart Association|May 17, 2013
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activityMichelle A Berny-Lang, Joseph A Jakubowski, Atsuhiro Sugidachi, et al.
Veterinary Immunology and Immunopathology|April 15, 2008
Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activationInge Tarnow, Annemarie T Kristensen, Anne K R Krogh, et al.
Platelets|August 14, 2015
Aspirin response: Differences in serum thromboxane B2 levels between clinical studiesCharlotte Brun, Youssef Daali, Christophe Combescure, et al.
Thrombosis Research|December 1, 2009
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptorsHung Chang, Ivan B Yanachkov, Alan D Michelson, et al.
Platelets|August 13, 2010
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney functionMaria Lajer, Inge Tarnow, Alan D Michelson, et al.
Circulation|June 21, 2006
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistanceAndrew L Frelinger, Mark I Furman, Matthew D Linden, et al.
Scientific Reports|December 1, 2018
Publisher Correction: GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet ActivationElena Smolensky Koganov, Alan D Michelson, Ivan B Yanachkov, et al.
Scientific Reports|September 30, 2018
GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet ActivationElena Smolensky Koganov, Alan D Michelson, Ivan B Yanachkov, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Immunity|January 7, 2022
Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemiaValentina Poli, Marco Di Gioia, Martha Sola-Visner, et al.
The American Journal of Cardiology|October 30, 2003
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregationAndrew L Frelinger, Mark I Furman, Marc R Barnard, et al.
Journal of the American Heart Association|May 17, 2013
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activityMichelle A Berny-Lang, Joseph A Jakubowski, Atsuhiro Sugidachi, et al.
Veterinary Immunology and Immunopathology|April 15, 2008
Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activationInge Tarnow, Annemarie T Kristensen, Anne K R Krogh, et al.
Platelets|August 14, 2015
Aspirin response: Differences in serum thromboxane B2 levels between clinical studiesCharlotte Brun, Youssef Daali, Christophe Combescure, et al.
Thrombosis Research|December 1, 2009
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptorsHung Chang, Ivan B Yanachkov, Alan D Michelson, et al.
Platelets|August 13, 2010
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney functionMaria Lajer, Inge Tarnow, Alan D Michelson, et al.
Circulation|June 21, 2006
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistanceAndrew L Frelinger, Mark I Furman, Matthew D Linden, et al.
Scientific Reports|December 1, 2018
Publisher Correction: GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet ActivationElena Smolensky Koganov, Alan D Michelson, Ivan B Yanachkov, et al.
Scientific Reports|September 30, 2018
GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet ActivationElena Smolensky Koganov, Alan D Michelson, Ivan B Yanachkov, et al.
Pageof 10